Navigation Links
LSUHSC research identifies enzyme that makes survival molecule for key vision cells
Date:6/26/2009

New Orleans, LA Research lead by Dr. Nicolas Bazan, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, identifying an enzyme that makes neuroprotectin D1 which specifically and selectively protects retinal cells key for vision, will be published in the June 26, 2009 issue of the Journal of Biological Chemistry.

Dr. Bazan's research team previously discovered neuroprotectin D1 (NPD1), a naturally produced chemical messenger that protects cells from injury caused by free radicals and other oxidative stress. Neuroprotectin D1 is derived from the omega-3 fatty acid, DHA (docosahexaenoic acid) which is present in both brain and retinal cells.

Retinal pigment epithelial (RPE) cells are essential for the survival of rod and cone photoreceptor cells. RPE cells regulate the renewal of the tips of photoreceptor cells among other functions. When RPE cells do not function properly, photoreceptor cells are damaged and can die, leading to decreased vision and eventual blindness as in such conditions as retinitis pigmentosa and age-related macular degeneration. A number of stressors, including free radicals, damage RPE cells. Dr. Bazan's lab has shown that RPE cells produce NPD1 in response to oxidative stress. The focus of this research project was to further define that process.

The LSUHSC team's main participant was Jorgelina Calandria, a PhD student in the LSUHSC Neuroscience Center Graduate Program working with Dr. Bazan, along with Pranab Mukherjee, PhD, Research Assistant Professor. Calandria developed a stable cell line to explore the role of an enzyme called 15-LOX-1 that they believed might play a key role in the process of converting DHA into NPD1. They designed a series of experiments using cells with, and those deficient in, 15-LOX-1, and measured response to oxidative stress. They found that the cells deficient in 15-LOX-1 were more vulnerable and susceptible to cell
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. LSUHSC research finds single gene controls growth of some cancers
2. LSUHSC researchers first to document early signs for diabetes in kids as young as 7
3. LSUHSC dental researcher funded to develop better dental materials
4. LSUHSC research shows fish oil protects against diseases like Parkinsons
5. LSUHSC research may benefit diabetes by increasing understanding of how to control islet cell growth
6. LSUHSCs England leads development of new testing guidelines for common nerve disorder
7. LSUHSCs Dr. Xiao Cheng Wu co-authors annual report to the nation on cancer
8. LSUHSCs Fontham makes history
9. LSUHSC public health contributes to estimate of HPV-related cancers
10. LSUHSC awarded grant to address nursing shortage
11. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... PA (June 19, 2013) In early April, senior ... met in Hartford, Connecticut, to discuss one question: how ... event? , The preliminary results of this ... Active Shooter Events: The Hartford Consensus ," a concept ... Journal of Trauma and Acute Care Surgery ...
(Date:6/19/2013)... of Americans are on at least one prescription ... Clinic researchers say. Antibiotics, antidepressants and painkilling opioids ... percent of patients are on five or more ... in the journal Mayo Clinic Proceedings . ... Dr. Jennifer St. Sauver talking about the study, ...
(Date:6/19/2013)... California (PRWEB) June 19, 2013 Effective Environmental ... launch of new websites. These online links are devoted to ... Septic Tank cleaner, Organic Odor Control Mold Magician and others. ... for fish and animals in the water as well as ... and sludge buildup that can accumulate at the bottom of ...
(Date:6/19/2013)... YOKOHAMA, Japan Leading Japanese pharmaceutical companies, along ... Melinda Gates Foundation, pledged their commitment to bolster ... Health Innovative Technology Fund (GHIT Fund), at a ... the fifth Tokyo International Conference on African Development ... partners including the Ministry of Health, Labour ...
(Date:6/19/2013)... Ky. (PRWEB) June 19, 2013 Dental ... during sedation because from minor to moderate sedation, a ... Oregon Board of Dentistry is the latest to update ... moderate and deep sedation in an effort to increase ... the Oregon Dental Practice Act goes into effect July ...
Breaking Medicine News(10 mins):Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3
... many biological processes also may play a role in memory, ... California and the National Institute on Aging at the National ... the Journal of Neuroscience, agree with research by ... Both studies found that mice lacking the protein SIRT1 exhibited ...
... in specific brain regions in female patients with irritable bowel ... the abdomen, along with diarrhea, constipation or both. ... University, the study appears in the July issue of the ... that IBS is associated with both decreases and increases in ...
... HealthDay Reporter , WEDNESDAY, July 21 (HealthDay News) ... be candidates for vaginal birth in future pregnancies, say ... Gynecologists. "These guidelines emphasize again that a trial ... most women," said one of the authors of the ...
... 2010 (Oakland, Calif.) A total joint replacement registry ... patient safety, quality of care, cost-effectiveness and research, according ... editions of Clinical Orthopedics and Related Research , ... Surgeons. Kaiser Permanente,s Total Joint Replacement Registry ...
... Against the backdrop of some of the globe,s fastest ... a report launched today at the XVIII International AIDS ... a new model for scaling up treatment and prevention ... The report, "Prevention and Treatment of HIV/AIDS amongst Drug ...
... July 22, 2010 -- Child abuse is a serious problem ... United States alone. The American Academy of Pediatrics and ... abuse into four categories including neglect, physical abuse, sexual abuse, ... includes the abusive use of drugs on children. A ...
Cached Medicine News:Health News:SIRT1 gene important for memory 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 3Health News:Vaginal Delivery May Be OK After C-Section 2Health News:Vaginal Delivery May Be OK After C-Section 3Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 2Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 3Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 4Health News:The malicious use of pharmaceuticals: An under-recognized form of child abuse 2
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- Today leading ... all new data ranking Pharmaceutical web sites for usability, ... Sciences, User Experience Cloud platform, which compares how people ... on the web. The top three performers ... convert people overall. The bottom performers have usability problems, ...
(Date:6/19/2013)... 19, 2013 Today MedeAnalytics, a leading ... next-generation of its Employer Group and Individual ... to provide their employer groups an intuitive and ... and prescription drug claims, network utilization, and overall ... ) "Employer Group and Individual ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... Bristol-Myers Squibb, Company and Gilead Sciences, ... -, PRINCETON, N.J. and FOSTER CITY, Calif., ... BMY ) and Gilead Sciences, Inc.,(Nasdaq: GILD ... ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300,mg) ...
... to Compare Genous vs. Drug-Eluting and Bare ... ... Enrollment in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered ... in April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and ...
Cached Medicine Technology:Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Medicine Products: